Atlas FDA

LIAISON® XL Murex Anti-HBc and LIAISON® XL Murex Control Anti-HBc

FDA premarket approval P180038/S008 · decided 2021-12-27

Approval details

PMA number
P180038
Supplement
S008
Supplement type
30-Day Notice
Supplement reason
Process Change - Manufacturer/Sterilizer/Packager/Supplier
Trade name
LIAISON® XL Murex Anti-HBc and LIAISON® XL Murex Control Anti-HBc
Generic name
Test, Hepatitis B (B Antigen, B Surface Antigen, Be Antigen)
Applicant
DiaSorin, Inc.
Date received
2021-11-23
Decision date
2021-12-27
Days to decision
34 days
Decision code
OK30
Product code
LOM
Advisory committee
Microbiology
Expedited review
No
Location
Stillwater, MN
Statement
Changes allowing harmonization of product QC workflows.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
LIAISON Murex HBsAg Qual; LIAISON XL; LIAISON diluteX (K260770)DiaSorin, Inc.2026-06-04
LIAISON® XL MUREX Anti-HDV (318260); LIAISON® XL MUREX Control Anti-HDV (318261) (DEN250032)DiaSorin, Inc.2025-12-23
LIAISON VZV IgG HT, LIAISON Control VZV IgG HT (K231214)DiaSorin, Inc.2023-10-27
LIAISON Anti-HAV; LIAISON XS (K223403)DiaSorin, Inc.2022-12-09
LIAISON Calprotectin, LIAISON Q.S.E.T. Device Plus (K213858)DiaSorin, Inc.2022-07-26
LIAISON MeMed BV, LIAISON MeMed BV Control Set (K213936)DiaSorin, Inc.2022-07-14
LIAISON Ferritin (K193650)DiaSorin, Inc.2021-09-14
LIAISON Lyme IgM, LIAISON Lyme IgM Control Set, LIAISON Lyme Total Antibody Plus (K202573)DiaSorin, Inc.2021-02-18